KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Current Assets (2016 - 2025)

NovoCure (NVCR) has disclosed Current Assets for 12 consecutive years, with $646.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 41.56% to $646.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $646.7 million through Dec 2025, down 41.56% year-over-year, with the annual reading at $646.7 million for FY2025, 41.56% down from the prior year.
  • Current Assets hit $646.7 million in Q4 2025 for NovoCure, down from $1.2 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $1.2 billion in Q3 2025 to a low of $646.7 million in Q4 2025.
  • Historically, Current Assets has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2022.
  • Biggest five-year swings in Current Assets: skyrocketed 178.76% in 2021 and later crashed 41.56% in 2025.
  • Year by year, Current Assets stood at $1.1 billion in 2021, then rose by 3.54% to $1.1 billion in 2022, then decreased by 6.94% to $1.0 billion in 2023, then increased by 6.98% to $1.1 billion in 2024, then plummeted by 41.56% to $646.7 million in 2025.
  • Business Quant data shows Current Assets for NVCR at $646.7 million in Q4 2025, $1.2 billion in Q3 2025, and $1.1 billion in Q2 2025.